Microalbuminuria prevalence study in hypertensive type 2 diabetic patients in Malaysia

Medical Journal of Malaysia

Volumn 61, Issue 4, 2006, Pages 457-465

  Kong, N C T ^a,f   Chia, Y C ^b   Khalid, B A K ^a   Juwita, S ^c   Samiah Yasmin, A K ^a   Yap, L Y ^b   Norlaila, M ^a   Menon, J ^d   Tan, C ^e   Fung, Y K ^d  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^b UNIVERSITY OF MALAYA   (Malaysia)

^c SCHOOL OF PHYSICS   (Malaysia)

^d Queen Elizabeth Hospital   (Malaysia)

^e Kuching General Hospital   (Malaysia)

^f UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

Author keywords

Albuminuria; Diabetes mellitus; Diabetic nephropathy; Hypertension; Proteinuria; Type II

Indexed keywords

ALBUMIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; DIABETIC NEPHROPATHY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALAYSIA; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; RISK FACTOR; URINALYSIS;

AGED; ALBUMINURIA; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTENSION; MALAYSIA; MALE; MIDDLE AGED; PREVALENCE; PROTEINURIA;

EID: 33847075444     PISSN: 03005283     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992; 19: 403-18.
2. Diabetes e-Atlas, International Diabetes Foundation website: http://www.idf.org/e-atlas/home/ Accessed 6 January 2004.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-44.
4. Lim TO and Lim YN (Eds), 11th Annual Report of the Malaysian Renal and Transplantation Registry 2003.
5. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997; 157: 1413-18.
6. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 1996; 27: 2039.
7. Wang SL, Head J, Stevens L, Fuller JH. Excess mortality and its relation to hypertension and proteinuria in diabetic patients. The World Health Organization multinational study of vascular disease in diabetes. Diabetes Care 1996; 19: 305-12.
8. Parving HH. Diabetic nephropathy: prevention and treatment. Kidney Int 2001; 60: 2041-55.
9. Gross JL, de Azedevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: Diagnosis, Prevention and Treatment. Diabetes Care 2005; 28: 176-88.
10. American Diabetes Association. Nephropathy in Diabetes. Position Statement. Diabetes Care 2004; 27 (Suppl 1): S79-S83.
11. Spooren PF, Lekkerkerker JF, Vermes I. Micral-Test: a qualitative dipstick test for micro-albuminuria. Diabetes Res Clin Pract 1992; 18: 83- 87.
12. Mather HM, Chaturvedi N, Kehely AM, Comparison of prevalence and risk factors for microalbuminuria in South Asians and Europeans with type 2 diabetes mellitus. Diabet Med 1998; 15: 672-77.
13. Varghese A, Deepa R, Rema M, Mohan V. Prevalence of microalbuminuria in type 2 diabetes mellitus at a diabetes centre in southern India. Postgrad Med J 2001; 77: 399-402.
14. Tomura S, Kawada K, Saito K et al. Prevalence of microalbuminuria and relationship to the risk of cardiovascular disease in the Japanese population. Am J Nephrol 1999; 19: 13-20.
15. Lee WR, Lim HS. Thai AC et al. A window on the current status of diabetes mellitus in Singapore - the Diabcare-Singapore 1998 study. Singapore Med J 2001; 42: 501-7.
16. Wong JS. Proteinuria in diabetic patients in a primary health care setting in Sarawak. Med J Malaysia 2005; 60(2): 146-50.
17. Mafauzy M. Diabetes control and complications in private primary healthcare in Malaysia. Med J Malaysia 2005; 60(2): 212-17
18. Wu AYT, Kong NCT, de Leon FA, Pan CY, Tai TY, Yeung VTF et al for the MAPS Investigators. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia 2005; 48: 17-26.
19. Parving HH, Osterby R, Ritz E. Diabetic nephropathy. In: Brenner BM, editor. The Kidney, Philadelphia: Saunders, 2000; 1731-73.
20. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.
21. Ball SG. Benefits of blood pressure reduction in diabetic patients. J Hypertens Suppl 2003; 21 (Suppl 6): S31-S36.
22. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13.
23. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-62.
24. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44 Suppl 2: 14S-21S.
25. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
26. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
27. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003; 290: 2159-167.
28. Lam KS, Cheng IK, Janus ED, Pang RW. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995; 38: 604-9.
29. Smulders YM, van Eeden AE, Stehouwer CD, Weijers RN, Slaats EH, Silberbusch J. Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus? Eur J Clin Invest 1997; 27: 997-1002.
30. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260-69.
31. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356-60.
32. John L, Rao PS, Kanagasabapathy AS. Rate of progression of albuminuria in type II diabetes. Five-year prospective study from south India. Diabetes Care 1994; 17: 888-90.
33. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-78.
34. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-69.
35. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
36. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-78.
37. Song JH, Lee SW, Suh JH et al. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy. Clin Nephrol 2003; 60: 318-26.
38. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93.